

Michael Hecker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/964354/publications.pdf>

Version: 2024-02-01

64
papers

2,695
citations

185998

28
h-index

189595

50
g-index

66
all docs

66
docs citations

66
times ranked

4802
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy. <i>Pharmaceutics</i> , 2022, 14, 592.	2.0	8
2	Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis. <i>Journal of Personalized Medicine</i> , 2022, 12, 677.	1.1	3
3	Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis. <i>EBioMedicine</i> , 2022, 80, 104052.	2.7	7
4	Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110243.	1.1	1
5	Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis. , 2021, 12, 1272.		18
6	Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes. <i>Molecular Neurobiology</i> , 2021, 58, 2886-2896.	1.9	22
7	Principles and Practical Considerations for the Analysis of Disease-Associated Alternative Splicing Events Using the Gateway Cloning-Based Minigene Vectors pDESTsplice and pSpliceExpress. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5154.	1.8	8
8	Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson's Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 4008-4016.	0.9	11
9	Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642097564.	1.5	9
10	Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis. <i>Biomolecules</i> , 2021, 11, 1510.	1.8	19
11	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. <i>Cells</i> , 2020, 9, 175.	1.8	1
12	Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 139-145.	1.0	32
13	The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642096950.	1.5	9
14	Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, randomized analysis of relapse rates during pregnancy and the postnatal period. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 78-85.	1.9	12
15	Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 245-254.	1.9	68
16	General Principles of Immunotherapy in Neurological Diseases. <i>Contemporary Clinical Neuroscience</i> , 2019, , 387-421.	0.3	3
17	Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study. <i>PLoS ONE</i> , 2019, 14, e0211120.	1.1	17
18	Polypharmacy in patients with multiple sclerosis: a gender-specific analysis. <i>Biology of Sex Differences</i> , 2019, 10, 27.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Aberrant expression of alternative splicing variants in multiple sclerosis – A systematic review. <i>Autoimmunity Reviews</i> , 2019, 18, 721-732.	2.5	19
20	Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors. <i>Scientific Reports</i> , 2019, 9, 3743.	1.6	19
21	Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases. <i>Journal of Immunology</i> , 2019, 202, 2177-2187.	0.4	53
22	A genetic variant associated with multiple sclerosis inversely affects the expression of CD58 and microRNA-548ac from the same gene. <i>PLoS Genetics</i> , 2019, 15, e1007961.	1.5	17
23	Blood transcriptome profiling captures dysregulated pathways and response to treatment in neuroimmunological disease. <i>EBioMedicine</i> , 2019, 49, 2-3.	2.7	4
24	Association of smoking but not HLA-DRB1*15:01, <i><i>APOE</i></i> or body mass index with brain atrophy in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 661-668.	1.4	12
25	Interferon $\hat{2}$ -1a and $\hat{2}$ -1b for patients with multiple sclerosis: updates to current knowledge. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 137-153.	1.3	36
26	Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 193-201.	1.9	32
27	Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy. <i>Scientific Data</i> , 2018, 5, 180145.	2.4	12
28	Molekularbiologische Untersuchungen bei MS. , 2018, , 207-210.		0
29	Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis. <i>Scientific Reports</i> , 2017, 7, 42087.	1.6	37
30	High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution. <i>Molecular Neurobiology</i> , 2017, 54, 5511-5525.	1.9	16
31	Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 116-121.	1.0	11
32	High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1360-1380.	2.5	60
33	Comparative evaluation of patients'™ and physicians'™ satisfaction with interferon beta-1b therapy. <i>BMC Neurology</i> , 2016, 16, 181.	0.8	7
34	Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms. <i>Scientific Reports</i> , 2016, 6, 34512.	1.6	63
35	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	4.7	133
36	Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary. <i>Advances in Therapy</i> , 2016, 33, 834-847.	1.3	15

#	ARTICLE	IF	CITATIONS
37	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing—remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1202-1214.	1.4	40
38	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	0.6	15
39	Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. <i>Autoimmunity Reviews</i> , 2015, 14, 903-913.	2.5	61
40	Susceptibility variants in the CD58 gene locus point to a role of microRNA-548ac in the pathogenesis of multiple sclerosis. <i>Mutation Research - Reviews in Mutation Research</i> , 2015, 763, 161-167.	2.4	15
41	Molekularbiologische Untersuchungen bei multipler Sklerose. , 2015, , 211-214.		0
42	Fluorescent-increase kinetics of different fluorescent reporters used for qPCR depend on monitoring chemistry, targeted sequence, type of DNA input and PCR efficiency. <i>Mikrochimica Acta</i> , 2014, 181, 1689-1696.	2.5	62
43	Comprehensive Absolute Quantification of the Cytosolic Proteome of <i>Bacillus subtilis</i> by Data Independent, Parallel Fragmentation in Liquid Chromatography/Mass Spectrometry (LC/MSE). <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1008-1019.	2.5	102
44	MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16087-16110.	1.8	112
45	Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients’ individual gene expression in peripheral blood. <i>Molecular Neurobiology</i> , 2013, 48, 737-756.	1.9	35
46	Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2013, 10, 126.	3.1	14
47	Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon- β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e70626.	1.1	43
48	Epitope Predictions Indicate the Presence of Two Distinct Types of Epitope-Antibody-Reactivities Determined by Epitope Profiling of Intravenous Immunoglobulins. <i>PLoS ONE</i> , 2013, 8, e78605.	1.1	20
49	Network analysis of transcriptional regulation in response to intramuscular interferon- β -1a multiple sclerosis treatment. <i>Pharmacogenomics Journal</i> , 2012, 12, 134-146.	0.9	31
50	Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. <i>Journal of Neuroinflammation</i> , 2012, 9, 140.	3.1	50
51	Integration of MicroRNA Databases to Study MicroRNAs Associated with Multiple Sclerosis. <i>Molecular Neurobiology</i> , 2012, 45, 520-535.	1.9	58
52	MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Autoimmunity Reviews</i> , 2012, 11, 174-179.	2.5	95
53	Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis. <i>Autoimmunity Reviews</i> , 2012, 11, 180-190.	2.5	39
54	An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients. <i>Current Pharmaceutical Design</i> , 2012, 18, 4475-4484.	0.9	9

#	ARTICLE	IF	CITATIONS
55	Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy. <i>Pharmacogenomics</i> , 2011, 12, 423-432.	0.6	25
56	Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e29648.	1.1	33
57	Mass Spectrometric Characterization of Protein Structure Details Refines the Proteome Signature for Invasive Ductal Breast Carcinoma. <i>Journal of the American Society for Mass Spectrometry</i> , 2011, 22, 440-456.	1.2	25
58	Frequencies of Polymorphisms in Cytokines, Neurotransmitters and Adrenergic Receptors in Patients With Complex Regional Pain Syndrome Type I After Distal Radial Fracture. <i>Clinical Journal of Pain</i> , 2010, 26, 175-181.	0.8	35
59	Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN- β treatment in relapsing remitting MS. <i>Pharmacogenomics</i> , 2010, 11, 147-161.	0.6	42
60	Integrative modeling of transcriptional regulation in response to antirheumatic therapy. <i>BMC Bioinformatics</i> , 2009, 10, 262.	1.2	33
61	Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 395, 2443-2456.	1.9	31
62	Gene regulatory network inference: Data integration in dynamic models—A review. <i>BioSystems</i> , 2009, 96, 86-103.	0.9	663
63	Monitoring of multiple sclerosis immunotherapy. <i>Journal of Neurology</i> , 2008, 255, 48-57.	1.8	84
64	Molecular discrimination of responders and nonresponders to anti-TNF α therapy in rheumatoid arthritis by etanercept. <i>Arthritis Research and Therapy</i> , 2008, 10, R50.	1.6	108